CMPX 株価分析 — Compass Therapeutics Inc. (Healthcare >> Biotechnology)
CMPX に関するよくある質問
CMPXのROE(自己資本利益率)は?
Compass Therapeutics Inc.のROEは-36.56%です。
CMPXの配当利回りは?
Compass Therapeutics Inc.の配当利回りは0.00%です。
CMPXの品質スコア(Quality Score)は?
当社のAIはCMPXの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CMPXは今が買い時ですか?
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CMPXはどのセクターに属しますか?
Compass Therapeutics Inc.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
CMPX AI Analysis Summary
Our AI summary for CMPX: Compass Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -36.56%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.91
Price
-0.03
(-1.55%)
Day Change
|
|
|---|
CMPX, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 81 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.91 |
| PBV / Sector |
1.87 / 5.20
|
| Earning Per Share | -0.37 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
5.05 M
GREAT
|
| Average 1W Daily Value |
5.68 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:39 |
| Symbol | CMPX |
| Name | COMPASS THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 180.09 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 349.37 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 80 Guest Street, Boston, MA, United States, 02135
Phone: 617 500 8099
Website: https://www.compasstherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google